Stephen A. Strickland, MD, MSCI

Articles

Key Takeaways: The Current Landscape and Future of CML Care

January 10th 2025

Panelists discuss how it is an exciting time for chronic myeloid leukemia (CML) treatment, with many options including 6 different drugs that have been very successful for patients, which give clinicians multiple options to tailor the therapy to their patients and consider whether CML could be curable.

ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment

January 10th 2025

Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.

Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection

January 3rd 2025

Panelists discuss how in selecting first-line therapy for patients with newly diagnosed chronic myeloid leukemia, clinicians must carefully weigh factors including the patient’s risk score, comorbidities, drug interaction potential, monitoring requirements, and cost considerations while recognizing that available tyrosine kinase inhibitor options (imatinib, nilotinib, dasatinib, and bosutinib) have similar efficacy but distinct safety and tolerability profiles.

Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

January 3rd 2025

Panelists discuss how clinicians should implement regular cardiovascular monitoring and dose modifications for ponatinib-associated toxicities while being vigilant for asciminib’s key adverse events, including thrombocytopenia, pancreatic dysfunction, and hypertension, with appropriate dose adjustments and supportive care as needed.

Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

December 20th 2024

Panelists discuss how when choosing between asciminib and ponatinib for chronic myeloid leukemia treatment, key considerations include the patient’s mutation status, prior tyrosine kinase inhibitor therapy response, cardiovascular risk factors and comorbidities, and the differing safety profiles of the 2 drugs, with ponatinib generally having more cardiovascular concerns but broader mutation coverage vs asciminib’s more favorable tolerability but more specific targeting of BCR::ABL1.

Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

December 20th 2024

Panelists discuss how for patients with chronic myeloid leukemia who develop the T315I mutation, ponatinib and asciminib have demonstrated efficacy in the PACE and ASCEMBL trials, respectively, with ponatinib showing a major cytogenetic response rate in patients with T315I mutation and asciminib demonstrating superior major molecular response vs bosutinib.

Interpreting Milestones: Prioritizing the Patient Picture

December 13th 2024

Panelists discuss how mutation analysis should be considered when treatment fails to meet milestones or patients show loss of response to tyrosine kinase inhibitor (TKI) therapy, as this information helps determine whether to continue the current TKI or switch to an alternative agent based on the specific resistance profile.

Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

December 13th 2024

Panelists discuss how in standard clinical practice, response to first-line tyrosine kinase inhibitor therapy is monitored through regular molecular testing of BCR::ABL1 transcript levels, with key evaluations to assess whether patients achieve target milestone responses that predict long-term outcomes.

Dr. Strickland on the Diagnosis of ESCC

January 30th 2023

Stephen A. Strickland, MD, MSCI, discusses a step-by-step approach for the diagnosis and workup of esophageal squamous cell carcinoma.